CLEARANCE OF CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH ASTRAZENECA AND RECEIPT BY INNATE PHARMA OF $250M INITIAL PAYMENT
Marseille, France, July 7, 2015
Innate Pharma SA (Euronext Paris: FR0010331421 - IPH) today announced that the co-development and commercialization agreement with AstraZeneca on Innate Pharma's proprietary anti-NKG2A antibody, IPH2201 (see announcement press release as of April, 24, 2015), received HSR clearance[*]. The companies will now begin to work together to accelerate and broaden the development of IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune.
On June 30, 2015, Innate Pharma received the initial payment of $250 million from AstraZeneca.
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.
Its innovative approach has translated into major alliances with leaders in the biopharmaceutical industry such as Bristol-Myers Squibb, AstraZeneca and Novo Nordisk A/S.
The Company has two clinical-stage programs in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells. Innate Pharma's science also has potential in chronic inflammatory diseases.
Listed on Euronext-Paris, Innate Pharma is based in Marseille, France, and had 107 employees as at March 31, 2015.
Learn more about Innate Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma shares:
| ISIN code Ticker code | FR0010331421 IPH |
Disclaimer:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website or on Innate Pharma's website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
| Innate Pharma | ATCG Press |
| Laure-Hélène Mercier Director, Investor Relations Tel.: +33 (0)4 30 30 30 87 investors@innate-pharma.com | Marie Puvieux (France) Mob: +33 (0)6 10 54 36 72 Jean-Medhi Grangeon (outside France) Mob: +33 (0)6 62 22 00 24 |
| presse@atcg-partners.com |
[*] Hart-Scott-Rodino Antitrust Improvements Act, a set of amendments to the antitrust laws of the United States
